Xavier Reveles

Jun 28, 2017

Bioaffinity Technologies announced the addition of Xavier Reveles as director of operations. He will manage the commercialization of Bioaffinity's diagnostic and therapeutic products. Reveles has 25 years of experience as a clinical geneticist and was laboratory director for Oncopath Laboratory-START Cancer Center. 

More Like This

Jun 21, 2018

Garrett Lam

Garrett Lam will join Sera Prognostics as chief medical officer starting Sept. 4. He will direct all clinical development activities for the firm and direct a group of clinical operations professionals in support of the firm's collaborations. Lam is currently a professor and chairman of obstetrics and gynecology at the University of Tennessee College of Medicine-Chattanooga. Lam replaces Durlin Hickok, who has been Sera's CMO since 2011. Hickok will continue as an advisor to Sera. 

Jun 20, 2018

Kenneth Bloom

Kenneth Bloom has become chief medical officer of advanced pathology and genomic services at Invicro and Ambry Genetics, both part of Konica Minolta. Previously, he was president and head of oncology and immunotherapy at Human Longevity, and before that, chief medical officer of in vitro diagnostics, life sciences at General Electric. He also served as president and CEO of the medical group of Clarient Pathology Services, which was acquired by GE. Prior to that, he held various academic positions, including director of laboratory operations and chief information officer at the Rush Cancer Institute, clinical professor of pathology at the University of Southern California Keck School of Medicine, and associate professor of pathology at Rush Medical College. Bloom holds an MD from Rush Medical College and a BA from Grinnell College.

Jun 15, 2018

Henry Cole

Avant Diagnostics appointed Henry Cole a director of the company, effective June 9. He is president of Global Development International, a position he's held since 2007. He previously was president and corporate officer at Futures Group International and Futures Group Holdings. 

Jun 13, 2018

Chris Goulart

Vermillion has appointed Chris Goulart to the newly created position of senior vice president of commercial operations. He has held several sales, marketing, and business development positions, most recently at Natera where he was director of commercial development. He was also VP of sales and marketing for genetics laboratory joint venture between Fresenius Medical Chare and Shiel Holdings, and prior to that, Goulart was the director of international sales and managed care for Recombine, which was acquired by Cooper Surgical. 

Jun 13, 2018

Lawrence Firestone

Akonni Biosystems has appointed Lawrence Firestone to the role of executive vice president and CFO to bring the company through the commercialization phase of its business plan. Firestone has previously served as CEO, CFO, and COO in various technology firms.

Jun 13, 2018

Rohan Hastie, John Ryals,

Rohan Hastie was named president and CEO of Metabolon. He replaces John Ryals, who retired from those posts, but will remain on the company's board. Ryals has been president, CEO, and a board member of Metabolon since April 2002, when he cofounded the firm. 

Hastie joined Metabolon in September 2017 as chief business officer. Before that, he was president of consulting firm Arrow Life Sciences & Healthcare. He also has held leadership positions in diagnostics and corporate development at Hologic, where he was most recently president of Hologic Diagnostic Solutions.

Jun 13, 2018

Nicolas Vergauwe, Rudi Pauwels

Belgian point-of-need diagnostics firm miDiagnostics announced Nicolas Vergauwe is its new CEO and Rudi Pauwels is its new chairman of the board. Vergauwe was previously vice president of innovations at Biocartis, which he joined in 2012. Pauwels is a founder or cofounder of several firms including Tibotec, Virco, Galapagos Genomics, and Biocartis. He also is on Imec's scientific advisory board. 

Jun 12, 2018

Michael McCartney

Cancer Genetics has appointed Michael McCartney its chief commercial officer, effective immediately. McCartney was previously CEO of SciKon Innovation, an early-stage life science company. Before that, he was SciKon's COO. He has more than 20 years of experience in the life science space including stints at Roche, Siemens, and Abbott. 

Jun 07, 2018

Harold Harrison

Geisinger Director of Clinical Pathology and Director of Geisinger Regional Laboratories Harold Harrison was killed on Wednesday when the vehicle he drove crashed into a tree at Bucknell University. He was 67. 

The cause of the crash in unknown. News reports said that Harrison accelerated his vehicle through a red light. According to television station WNEP, the Union County Coroner's Office believes he suffered a medical emergency, which resulted in the crash. 

In a statement, Geisinger called Harrison "an intellectual powerhouse and a consummate clinical laboratory scientist [who] ensured excellence in clinical lab services for Geisinger and contributed to the field of laboratory quality assurance." 

Jun 06, 2018

Bob Englert, Steve Crouse

Vortex Biosciences has appointed Bob Englert as its new CEO. Englert, who was previously the firm's chief technology officer, replaces exiting CEO Gene Walther, who has resigned to pursue other interests and will step down both from his position as CEO and as a member of the company's board.

Englert has over 25 years of experience in medical devices and life sciences, with a particular focus on IVD, point of care, and digital health solutions. Before joining Vortex, he served as CEO and founder of Biomedtrics, a diabetes data management company, and prior to that he was COO of Pelikan Technologies. Earlier in his career, Englert also held multiple senior roles at Abbott Laboratories. He holds a BS in biology from the University of Illinois Urbana-Champaign.

Vortex also said that Steve Crouse, who has been the company's chief commercial officer since March 2016, will now assume the position of chief operating officer. Prior to joining Vortex, Crouse served as senior vice president of sales and marketing at Freeslate, a company focused on providing laboratory automation to chemical and pharmaceutical companies.

Jun 05, 2018

Sean Farrell

Tenet Diagnostics appointed Sean Farrell vice president of sales and strategy. He will lead efforts to enhance collaborative partnerships with self-funded employers, insurers, and health plans, as well as physician practices, addiction treatment clinics, and pain management organizations. Farrell was previously executive VP at Sagenex Labs and EVP sales and marketing at Addiction Labs. He was also previously regional manager of business development at Laboratory Corporation of America. 

Jun 05, 2018

Raymond Akers

Raymond Akers has resgined from the board of directors of Akers Biosciences, effective immediately. In a document filed with the US Securities and Exchange Commission dated June 1, the firm said that it believes Akers resigned due to "his significant differences with other members of the board regarding management of the company, its accounting and business practices, and its counsel." Last week, the company said that it had been granted a 180-day extension to meet a listing requirement of the Nasdaq calling for a minimum $1 per share closing bid price for 10 consecutive business days. The company added that the board's audit committee has been reviewing certain revenue recognition items for Q1 2018 and previous quarters. "The company believes Dr. Akers has not been fully cooperative in connection with such review," it said in its SEC document. 

May 31, 2018

Fred Ferrara

Vermillion COO Fred Ferrara has terminated his employment with the company, effective June 1, Vermillion said in a document filed with the US Securities and Exchange Commission. Ferrar joined the company in April 2015. Before landing at Vermillion, he held leadership roles in information technology and operations at Laboratory Corporation of America, and Dianon Systems. He also was CIO and Senior Vice President of Aurora Diagnostics' Anatomic Pathology Services. 

May 30, 2018

Franz Walt

Jersey, Channel Islands-based Quotient appointed Franz Walt as its CEO. He has 30 years of experience in leadership roles at Siemens Healthineers and Roche, Quotient said. He retired earlier this year as president of Siemens Healthineers, Laboratory Diagnostics, and was appointed interim CEO at Quotient in March.

May 25, 2018

Cynthia Collins

DermTech, a developer of non-invasive molecular dermatology tests, has appointed Cynthia Collins to its board of directors. Collins most recently served as CEO of Human Longevity. She has also been CEO/GM of GE Healthcare's cell therapy business, lab businesses, and Clarient Diagnostics. Prior to GE, Collins was president and CEO of GenVec. Before that she was group vice president for the cellular analysis business at Beckman Coulter. She has also held executive positions with Sequoia Pharmaceuticals and Clinical Micro Sensors, a subsidiary of Motorola.